• Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
  • Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
  • Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
  • Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
  • Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
  • Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide

Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide

Powder: Yes
Customized: Customized
Certification: GMP, ISO 9001, USP, BP, SGS
Suitable for: Elderly, Children, Adult
State: White Powder Lyophilized Powder
Purity: >98%
Customization:
Manufacturer/Factory
Gold Member Since 2021

Suppliers with verified business licenses

Shaanxi, China
Importers and Exporters
The supplier has import and export rights
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Experienced Team
The supplier has 6 foreign trading staff(s) and 3 staff(s) with over 6 years of overseas trading experience
Patents Awarded
The supplier had awarded 1 patents, you can check the Audit Report for more information
to see all verified strength labels (10)

Basic Info.

CAS No.
2023788-19-2
Test Method
HPLC
MOQ
1kg
Appearance
White Lyophilized Powder
Shelf Life
2 Years
Storage
Cool Dry Place
Delivery
Express 5-7 Days Arrive
Sample
Available
Grade
Pharmaceutical Grade
Product Name
Tirzepatide
Application
Weight Loss
Transport Package
Foil Bag
Specification
1kg Per Foil Bag, 10 Bags Per Carton, 25 Kg Per Dr
Trademark
Frazer
Origin
China
Production Capacity
1000boxes/Month

Product Description

Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide 
Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
Description

Tirzepatide (Mounjaro) is a novel medication indicated as an adjunct to diet and exercise in the treatment of patients with type 2 diabetes mellitus. Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to lower blood glucose levels.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 agonist that has been studied recently as a treatment for patients with noncirrhotic NASH (SYNERGY-NASH, NCT04166773) given its association with significant weight loss and improvement in features of metabolic syndrome in diabetes trials.
Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide

Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
Function

The addition of GIP which anatagonizes the central effects of GLP-1 to cause nausea is designed to improve tolerability and also allow for more aggressive dosing with increased systemic exposure. A recent post-hoc analysis showed significantly decreased NASH-related biomarkers and increased adiponectin in patients with T2DM

The weight-reducing actions of the GIPR-GLP1R co-agonist tirzepatide.Considerable interest is focused on the mechanisms of action of tirzepatide, a highly effective GIPR-GLP1R co-agonist that produces superior reductions in HbA1c and body weight, relative to that achieved with 1 mg once weekly of semaglutide in people with T2D. The GIPR is expressed in multiple regions of the mouse and human brain, in subsets of neurons and glial cells, with some hypothalamic and hindbrain cells exhibiting co-expression of the GIPR and GLP1R. Chemogenetic activation of GIPR + cells in the mouse hypothalamus acutely reduced food intake; however, co-administration of exendin-4 did not produce an additive reduction of food intake when compared to either intervention alone.

Therapy with tirzepatide, 5-15 mg once weekly produces 8-12% body weight reduction in people with T2D, prompting ongoing development of tirzepatide as a weight loss agent for people with overweight or obesity. The importance of GIP for the weight loss properties of tirzepatide in humans is uncertain; however, tirzepatide failed to reduce body weight in Glp1r−/- mice, implicating a dominant role for the GLP1R in the weight loss observed with this agent. Glucose-dependent insulinotropic polypeptide (GIP) has been shown to reduce the extent of aversive responses induced by GLP-1 in mice and rats and decrease nausea and vomiting in the shrew.

Application
  • Helps slow food leaving your stomach
  • Helps prevent your liver from making too much sugar
  • Helps the pancreas produce more insul when your blood sugar levels are high
  • Can help control blood glucose
  • Can reduce hyperglycemia, especially after meals
  • Can reduce fasting insul and fasting glucose
  • Can reduce hemoglobin A1c
  • Can decrease appetite and caloric intake, while inhibiting weight gain
  • Has been shown to lower triglyceride levels and oxidative stress from high LDL
  • Has been shown to help induce weight loss in obese patients with higher dosing
  • Helps decrease leptin and increase leptin sensitivity
  • Can increase the conversion of white fat to brown fat
Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide
 

Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide

Hot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 TirzepatideHot Sales Tirzepatide Gip GLP-1 Injection CAS 2023788-19-2 Tirzepatide

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Gold Member Since 2021

Suppliers with verified business licenses

Manufacturer/Factory
Registered Capital
1000000 RMB
Plant Area
501~1000 square meters